Report: Arbor Pharma goes on the block for $1B-plus

Damian Garde Private drugmaker Arbor Pharmaceuticals is looking for a buyer, according to Reuters, going on the market with a price tag that could exceed $ 1 billion. FierceBiotech ...

Report: In a big split, Baxter looks to relocate biopharma to Boston

John Carroll For months now rumors of a big prospective biotech relocation have been circulating in the hot Boston hub. And now the Boston Business Journal, a weekly with its ear to ...

Report: When it comes to drug spending, DOD pays the highest price

Carly Helfand In a recent study, the Government Accountability Office (GAO) took a sample of 78 widely used drugs, including both brand-named and generic products, and looked at prices ...

Report: Biopharma’s class of 2013 is laden with blockbusters

Damian Garde While 2013's number of approved drugs fell short of 2012's record haul, the class is likely to more than make up for that disparity in the dollar column, according ...

ThromboGenics is picking between billion-dollar bids, report says

Damian Garde Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as ...

Second drug spending report predicts double-digit increases coming

Eric Palmer In case anyone missed the latest forecast, drug prices were up last year and are going to continue to grow, perhaps at double-digit rates in some cases. The outlook comes ...

Report: Abingworth tees up $330M-plus to bankroll biotech bets

Damian Garde Life sciences venture outfit Abingworth is creeping up on a close for its 6th fund, according to Dow Jones Venturewire, reportedly outstripping its goal of $ 330 million ...

Report: Focus on Compliance Reduces Risk for Payers in the Medicare and Medicaid Markets

barbara.lempert Focus on Compliance Reduces Risk for Payers in the Medicare and Medicaid Markets, according to White Paper by TMG Health KING OF PRUSSIA, Pa., Dec. 27, 2013 /PRNewswire/ ...

Sanofi and Regeneron Report Positive Results with Sarilumab

mia.burns Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial Sarilumab, Given Subcutaneously Every Other ...

Karo Bio Announces 2013 Interim Report

mia.burns INTERIM REPORT JANUARY-SEPTEMBER 2013 The January–September period and the third quarter 2013 in brief Net sales amounted to MSEK 37.4 (24.6), whereof the third quarter ...

FDA staff report puts hurt on Amarin

Eric Palmer So what is the difference between a drug approved to treat very high triglycerides and one approved to treat merely high triglycerides? Thirty-six million more potential ...

Report: Ikaria eyes $2B sale after up-and-down run

Damian Garde Three years after pulling the plug on an IPO, New Jersey drugmaker Ikaria has put itself on the market, Reuters reports, looking to cash out for $ 2 billion or more. FierceBiotech ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS